The pharmaceutical landscape continues to evolve, with much R&D focusing on more specialised medicines. As the biological activity and specificity of the API increases, dosage strengths decrease – resulting in increased potency of the APIs in terms of occupational handling for drug product manufacture. Leaders in the development and manufacturing of potent molecules with specialist containment technology provide expertise in the safe and successful management of highly potent active pharmaceutical ingredients (HPAPIs). David O’Connell at PCI Pharma Services shares PCI’s contract development and manufacturing (CDMO) experience.

[gview file=”https://www.ipimediaworld.com/wp-content/uploads/2019/05/Highly-potent-molecules.pdf”]